MitoQ for Fatigue in Multiple Sclerosis

Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · May 24, 2017

Keywords

ClinConnect Summary

MitoQ is a potent antioxidant with potentially significant immunomodulatory and anti-inflammatory properties. While the cause of MS related fatigue is uncertain, the investigators believe that mitochondria dysfunction and resultant neuronal energy depletion may be an important contributor to fatigue in MS.

This clinical trial will evaluate the potential beneficial effects of MitoQ on MS fatigue. It will also explore the effects of MitoQ on cognitive function, quality of life and mood. If enrolled in the study, patients will take two capsules of the study drug or placebo at the same time ev...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • MS (any clinical subtype) as diagnosed by the 2010 McDonald criteria40;
• • Expanded Disability Status Scale (EDSS) score of 2 to 8,
• • Complaint of fatigue that has been persistent for at least two months;
• • Modified Fatigue Impact Scale (MFIS) score of 38 or greater
• Exclusion Criteria:
• • Treatment with systemic glucocorticoids in the prior six weeks;
• • Beck Depression Inventory (BDI) \>31 (severe depression);
• • Significant MS exacerbation in prior 30 days;
• • Previous use of MitoQ or CoQ-10 within 30 days of screening appointment;
• • Use of non-research-pharmacy-administered MitoQ or CoQ-10 during the duration of the study;
• • Other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus) that might increase risk of patient experiencing adverse events),
• • Pregnancy or intending to become pregnant or breastfeeding;
• • Unable to complete the self-report forms;
• • Unable to give informed consent;
• • Prisoners will be excluded.
• • Any condition which would make the patient, in the opinion of the investigator, unsuitable for the study.